查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1905110

日本药物警戒市场报告（按服务提供者、产品生命週期、类型、流程、治疗领域、最终用途和地区划分，2026-2034 年）

Japan Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 117 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2025年，日本药物警戒市场规模达5.414亿美元。展望未来， IMARC Group预计到2034年，该市场规模将达到10.22亿美元，2026年至2034年间的复合年增长率（CAGR）为7.32%。巨量资料分析、人工智慧和机器学习工具需求的不断增长，透过提高讯号检测和风险评估效率，彻底改变了药物警戒领域，并推动了市场成长。

本报告解答的关键问题：

  • 日本药物警戒市场目前的表现如何？未来几年又将如何发展？
  • 新冠疫情对日本药物警戒市场产生了哪些影响？
  • 日本药物警戒市场按服务提供者分類的组成是怎样的？
  • 日本药物警戒市场依产品生命週期分類的组成是怎样的？
  • 日本药物警戒市场按类型分類的组成是怎样的？
  • 日本药物警戒市场依流程分類的组成是怎样的？
  • 日本药物警戒市场按治疗领域分類的组成是怎样的？
  • 日本药物警戒市场依最终用途分類的组成是怎样的？
  • 日本药物警戒市场价值链的各个阶段有哪些？
  • 日本药物警戒的关键驱动因素和挑战是什么？
  • 日本药物警戒市场的结构是怎么样的？主要参与者有哪些？
  • 日本药物警戒市场的竞争程度如何？

目录

第一章：序言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 数据来源
  • 市场估算
  • 预测方法

第三章：执行概要

第四章：日本药物警戒市场－简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本药物警戒市场概况

  • 历史及当前市场趋势（2020-2025）
  • 市场预测（2026-2034）

第六章：日本药物警戒市场－依服务提供者划分

  • 内部
  • 合约外包

第七章：日本药物警戒市场－依产品生命週期划分

  • 临床前
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第八章：日本药物警戒市场－按类型划分

  • 自发性报告
  • 加强不良反应报告
  • 针对性的自发性报告
  • 伫列事件监测
  • 电子健康记录挖掘

第九章：日本药物警戒市场－依流程细分

  • 案例资料管理
  • 讯号检测
  • 风险管理系统

第十章：日本药物警戒市场－依治疗领域划分

  • 肿瘤学
  • 神经病学
  • 心臟病学
  • 呼吸系统
  • 其他的

第十一章：日本药物警戒市场－以最终用途划分

  • 製药公司
  • 生技公司
  • 医疗器材公司
  • 其他的

第十二章：日本药物警戒市场－按地区划分

  • 关东地区
  • 关西/近畿地区
  • 中部/中部地区
  • 九州·冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

第十三章：日本药物警戒市场－竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳制胜策略
  • 竞争格局分析
  • 公司评估象限

第十四章：关键参与者简介

第十五章：日本药物警戒市场－产业分析

  • 驱动因素、限制因素和机会
  • 波特五力分析
  • 价值链分析

第十六章：附录

简介目录
Product Code: SR112026A19290

Japan pharmacovigilance market size reached USD 541.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,022.0 Million by 2034, exhibiting a growth rate (CAGR) of 7.32% during 2026-2034. The increasing demand for big data analytics, artificial intelligence, and machine learning tools, which has revolutionized pharmacovigilance by enabling more efficient signal detection and risk assessment, is driving the market.

Pharmacovigilance is a crucial aspect of healthcare and drug regulation. It involves the systematic monitoring, assessment, and reporting of adverse effects and safety concerns associated with pharmaceutical products, including prescription medications, vaccines, and over-the-counter drugs. The primary goal of pharmacovigilance is to ensure the safety and effectiveness of these products throughout their lifecycle. Healthcare professionals, pharmaceutical companies, and regulatory agencies collaborate in this process. They collect and analyze data on adverse events and side effects reported by patients and healthcare providers. If a potential safety concern arises, appropriate actions, such as product labeling updates, warnings, or even product recalls, may be taken to protect public health. Pharmacovigilance helps identify previously unknown or rare adverse effects, ensuring that drugs on the market remain safe for patients. This ongoing monitoring and risk assessment contribute to the continuous improvement of drug safety and the overall quality of healthcare.

Japan Pharmacovigilance Market Trends:

The pharmacovigilance market in Japan is experiencing robust growth, primarily due to several interconnected drivers. Firstly, the escalating regional demand for healthcare services has led to an increased consumption of medicines, amplifying the need for vigilant monitoring of drug safety. Additionally, the rising prevalence of chronic diseases and the introduction of new and complex therapies have further fueled the expansion of the pharmacovigilance market. Moreover, regulatory agencies in Japan are tightening their oversight of drug safety, imposing stringent reporting requirements on pharmaceutical companies. This has necessitated the outsourcing of pharmacovigilance activities to specialized service providers, driving market growth. Simultaneously, the growing awareness among healthcare professionals and patients about the importance of adverse event reporting has led to increased pharmacovigilance efforts. Moreover, advancements in technology, including artificial intelligence and big data analytics, which have revolutionized pharmacovigilance by enhancing the efficiency and accuracy of adverse event detection, are expected to drive the market in Japan during the forecast period.

Japan Pharmacovigilance Market Segmentation:

Service Provider Insights:

  • In-house
  • Contract Outsourcing

Product Life Cycle Insights:

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Type Insights:

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Process Flow Insights:

  • Case Data Management
    • Case Logging
    • Case Data Analysis
    • Medical Reviewing and Reporting
  • Signal Detection
    • Adverse Event Logging
    • Adverse Event Analysis
    • Adverse Event Review and Reporting
  • Risk Management System
    • Risk Evaluation System
    • Risk Mitigation System

Therapeutic Area Insights:

  • Oncology
  • Neurology
  • Cardiology
  • Respiratory Systems
  • Others

End Use Insights:

  • Pharmaceuticals Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Others

Regional Insights:

  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan pharmacovigilance market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan pharmacovigilance market?
  • What is the breakup of the Japan pharmacovigilance market on the basis of service provider?
  • What is the breakup of the Japan pharmacovigilance market on the basis of product life cycle?
  • What is the breakup of the Japan pharmacovigilance market on the basis of type?
  • What is the breakup of the Japan pharmacovigilance market on the basis of process flow?
  • What is the breakup of the Japan pharmacovigilance market on the basis of therapeutic area?
  • What is the breakup of the Japan pharmacovigilance market on the basis of end use?
  • What are the various stages in the value chain of the Japan pharmacovigilance market?
  • What are the key driving factors and challenges in the Japan pharmacovigilance?
  • What is the structure of the Japan pharmacovigilance market and who are the key players?
  • What is the degree of competition in the Japan pharmacovigilance market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmacovigilance Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Pharmacovigilance Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Pharmacovigilance Market - Breakup by Service Provider

  • 6.1 In-house
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Contract Outsourcing
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)

7 Japan Pharmacovigilance Market - Breakup by Product Life Cycle

  • 7.1 Pre-clinical
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Phase I
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)
  • 7.3 Phase II
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2020-2025)
    • 7.3.3 Market Forecast (2026-2034)
  • 7.4 Phase III
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2020-2025)
    • 7.4.3 Market Forecast (2026-2034)
  • 7.5 Phase IV
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2020-2025)
    • 7.5.3 Market Forecast (2026-2034)

8 Japan Pharmacovigilance Market - Breakup by Type

  • 8.1 Spontaneous Reporting
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 Intensified ADR Reporting
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)
  • 8.3 Targeted Spontaneous Reporting
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2020-2025)
    • 8.3.3 Market Forecast (2026-2034)
  • 8.4 Cohort Event Monitoring
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2020-2025)
    • 8.4.3 Market Forecast (2026-2034)
  • 8.5 EHR Mining
    • 8.5.1 Overview
    • 8.5.2 Historical and Current Market Trends (2020-2025)
    • 8.5.3 Market Forecast (2026-2034)

9 Japan Pharmacovigilance Market - Breakup by Process Flow

  • 9.1 Case Data Management
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Segmentation
      • 9.1.3.1 Case Logging
      • 9.1.3.2 Case Data Analysis
      • 9.1.3.3 Medical Reviewing and Reporting
    • 9.1.4 Market Forecast (2026-2034)
  • 9.2 Signal Detection
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Segmentation
      • 9.2.3.1 Adverse Event Logging
      • 9.2.3.2 Adverse Event Analysis
      • 9.2.3.3 Adverse Event Review and Reporting
    • 9.2.4 Market Forecast (2026-2034)
  • 9.3 Risk Management System
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Segmentation
      • 9.3.3.1 Risk Evaluation System
      • 9.3.3.2 Risk Mitigation System
    • 9.3.4 Market Forecast (2026-2034)

10 Japan Pharmacovigilance Market - Breakup by Therapeutic Area

  • 10.1 Oncology
    • 10.1.1 Overview
    • 10.1.2 Historical and Current Market Trends (2020-2025)
    • 10.1.3 Market Forecast (2026-2034)
  • 10.2 Neurology
    • 10.2.1 Overview
    • 10.2.2 Historical and Current Market Trends (2020-2025)
    • 10.2.3 Market Forecast (2026-2034)
  • 10.3 Cardiology
    • 10.3.1 Overview
    • 10.3.2 Historical and Current Market Trends (2020-2025)
    • 10.3.3 Market Forecast (2026-2034)
  • 10.4 Respiratory Systems
    • 10.4.1 Overview
    • 10.4.2 Historical and Current Market Trends (2020-2025)
    • 10.4.3 Market Forecast (2026-2034)
  • 10.5 Others
    • 10.5.1 Historical and Current Market Trends (2020-2025)
    • 10.5.2 Market Forecast (2026-2034)

11 Japan Pharmacovigilance Market - Breakup by End Use

  • 11.1 Pharmaceuticals Companies
    • 11.1.1 Overview
    • 11.1.2 Historical and Current Market Trends (2020-2025)
    • 11.1.3 Market Forecast (2026-2034)
  • 11.2 Biotechnology Companies
    • 11.2.1 Overview
    • 11.2.2 Historical and Current Market Trends (2020-2025)
    • 11.2.3 Market Forecast (2026-2034)
  • 11.3 Medical Device Companies
    • 11.3.1 Overview
    • 11.3.2 Historical and Current Market Trends (2020-2025)
    • 11.3.3 Market Forecast (2026-2034)
  • 11.4 Others
    • 11.4.1 Historical and Current Market Trends (2020-2025)
    • 11.4.2 Market Forecast (2026-2034)

12 Japan Pharmacovigilance Market - Breakup by Region

  • 12.1 Kanto Region
    • 12.1.1 Overview
    • 12.1.2 Historical and Current Market Trends (2020-2025)
    • 12.1.3 Market Breakup by Service Provider
    • 12.1.4 Market Breakup by Product Life Cycle
    • 12.1.5 Market Breakup by Type
    • 12.1.6 Market Breakup by Process Flow
    • 12.1.7 Market Breakup by Therapeutic Area
    • 12.1.8 Market Breakup by End Use
    • 12.1.9 Key Players
    • 12.1.10 Market Forecast (2026-2034)
  • 12.2 Kansai/Kinki Region
    • 12.2.1 Overview
    • 12.2.2 Historical and Current Market Trends (2020-2025)
    • 12.2.3 Market Breakup by Service Provider
    • 12.2.4 Market Breakup by Product Life Cycle
    • 12.2.5 Market Breakup by Type
    • 12.2.6 Market Breakup by Process Flow
    • 12.2.7 Market Breakup by Therapeutic Area
    • 12.2.8 Market Breakup by End Use
    • 12.2.9 Key Players
    • 12.2.10 Market Forecast (2026-2034)
  • 12.3 Central/ Chubu Region
    • 12.3.1 Overview
    • 12.3.2 Historical and Current Market Trends (2020-2025)
    • 12.3.3 Market Breakup by Service Provider
    • 12.3.4 Market Breakup by Product Life Cycle
    • 12.3.5 Market Breakup by Type
    • 12.3.6 Market Breakup by Process Flow
    • 12.3.7 Market Breakup by Therapeutic Area
    • 12.3.8 Market Breakup by End Use
    • 12.3.9 Key Players
    • 12.3.10 Market Forecast (2026-2034)
  • 12.4 Kyushu-Okinawa Region
    • 12.4.1 Overview
    • 12.4.2 Historical and Current Market Trends (2020-2025)
    • 12.4.3 Market Breakup by Service Provider
    • 12.4.4 Market Breakup by Product Life Cycle
    • 12.4.5 Market Breakup by Type
    • 12.4.6 Market Breakup by Process Flow
    • 12.4.7 Market Breakup by Therapeutic Area
    • 12.4.8 Market Breakup by End Use
    • 12.4.9 Key Players
    • 12.4.10 Market Forecast (2026-2034)
  • 12.5 Tohoku Region
    • 12.5.1 Overview
    • 12.5.2 Historical and Current Market Trends (2020-2025)
    • 12.5.3 Market Breakup by Service Provider
    • 12.5.4 Market Breakup by Product Life Cycle
    • 12.5.5 Market Breakup by Type
    • 12.5.6 Market Breakup by Process Flow
    • 12.5.7 Market Breakup by Therapeutic Area
    • 12.5.8 Market Breakup by End Use
    • 12.5.9 Key Players
    • 12.5.10 Market Forecast (2026-2034)
  • 12.6 Chugoku Region
    • 12.6.1 Overview
    • 12.6.2 Historical and Current Market Trends (2020-2025)
    • 12.6.3 Market Breakup by Service Provider
    • 12.6.4 Market Breakup by Product Life Cycle
    • 12.6.5 Market Breakup by Type
    • 12.6.6 Market Breakup by Process Flow
    • 12.6.7 Market Breakup by Therapeutic Area
    • 12.6.8 Market Breakup by End Use
    • 12.6.9 Key Players
    • 12.6.10 Market Forecast (2026-2034)
  • 12.7 Hokkaido Region
    • 12.7.1 Overview
    • 12.7.2 Historical and Current Market Trends (2020-2025)
    • 12.7.3 Market Breakup by Service Provider
    • 12.7.4 Market Breakup by Product Life Cycle
    • 12.7.5 Market Breakup by Type
    • 12.7.6 Market Breakup by Process Flow
    • 12.7.7 Market Breakup by Therapeutic Area
    • 12.7.8 Market Breakup by End Use
    • 12.7.9 Key Players
    • 12.7.10 Market Forecast (2026-2034)
  • 12.8 Shikoku Region
    • 12.8.1 Overview
    • 12.8.2 Historical and Current Market Trends (2020-2025)
    • 12.8.3 Market Breakup by Service Provider
    • 12.8.4 Market Breakup by Product Life Cycle
    • 12.8.5 Market Breakup by Type
    • 12.8.6 Market Breakup by Process Flow
    • 12.8.7 Market Breakup by Therapeutic Area
    • 12.8.8 Market Breakup by End Use
    • 12.8.9 Key Players
    • 12.8.10 Market Forecast (2026-2034)

13 Japan Pharmacovigilance Market - Competitive Landscape

  • 13.1 Overview
  • 13.2 Market Structure
  • 13.3 Market Player Positioning
  • 13.4 Top Winning Strategies
  • 13.5 Competitive Dashboard
  • 13.6 Company Evaluation Quadrant

14 Profiles of Key Players

  • 14.1 Company A
    • 14.1.1 Business Overview
    • 14.1.2 Services Offered
    • 14.1.3 Business Strategies
    • 14.1.4 SWOT Analysis
    • 14.1.5 Major News and Events
  • 14.2 Company B
    • 14.2.1 Business Overview
    • 14.2.2 Services Offered
    • 14.2.3 Business Strategies
    • 14.2.4 SWOT Analysis
    • 14.2.5 Major News and Events
  • 14.3 Company C
    • 14.3.1 Business Overview
    • 14.3.2 Services Offered
    • 14.3.3 Business Strategies
    • 14.3.4 SWOT Analysis
    • 14.3.5 Major News and Events
  • 14.4 Company D
    • 14.4.1 Business Overview
    • 14.4.2 Services Offered
    • 14.4.3 Business Strategies
    • 14.4.4 SWOT Analysis
    • 14.4.5 Major News and Events
  • 14.5 Company E
    • 14.5.1 Business Overview
    • 14.5.2 Services Offered
    • 14.5.3 Business Strategies
    • 14.5.4 SWOT Analysis
    • 14.5.5 Major News and Events

15 Japan Pharmacovigilance Market - Industry Analysis

  • 15.1 Drivers, Restraints, and Opportunities
    • 15.1.1 Overview
    • 15.1.2 Drivers
    • 15.1.3 Restraints
    • 15.1.4 Opportunities
  • 15.2 Porters Five Forces Analysis
    • 15.2.1 Overview
    • 15.2.2 Bargaining Power of Buyers
    • 15.2.3 Bargaining Power of Suppliers
    • 15.2.4 Degree of Competition
    • 15.2.5 Threat of New Entrants
    • 15.2.6 Threat of Substitutes
  • 15.3 Value Chain Analysis

16 Appendix